Journal Logo

Most Popular Articles

Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma

Wolfe, Zachary; Friedland, Julie C.; Ginn, Sarah; More

Melanoma Research. : May 12, 2022

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

Hodi, F. Stephen; Chapman, Paul B.; Sznol, Mario; More

Melanoma Research. 31(1):67-75, February 2021.

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform

Bisschop, Cornelis; ter Elst, Arja; Bosman, Lisette J.; More

Melanoma Research. 28(2):96-104, April 2018.

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis

Ziegler, Johanna S.; Kroeze, Stephanie; Hilbers, Marie-Luise; More

Melanoma Research. 30(6):552-561, December 2020.

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Bao, Riyue; Surriga, Oliver; Olson, Daniel J.; More

Melanoma Research. 31(1):27-37, February 2021.

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Vera Aguilera, Jesus; Paludo, Jonas; McWilliams, Robert R.; More

Melanoma Research. 30(4):364-375, August 2020.

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Mantia, Charlene M.; Werner, Lillian; Stwalley, Brian; More

Melanoma Research. 32(1):35-44, February 2022.

Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade

Anderson, Katie L.; Snyder, Kristin M.; Ito, Daisuke; More

Melanoma Research. 30(2):147-158, April 2020.

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013–2016

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study

Meyer, Nicolas; Pérol, David; Duval-Modeste, Anne-Bénédicte; More

Melanoma Research. : May 27, 2022

Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma

Mulder, Evalyn E.A.P.; Damman, Jeffrey; Verver, Daniëlle; More

Melanoma Research. : April 21, 2022

Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging

Wisco, Oliver J.; Marson, Justin W.; Litchman, Graham H.; More

Melanoma Research. 32(2):98-102, April 2022.

Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases

Ingen-Housz-Oro, Saskia; Milpied, Brigitte; Badrignans, Marine; More

Melanoma Research. 32(3):205-210, June 2022.

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Holtkamp, Lodewijka H.J.; Chakera, Annette H.; Fung, Sebastian; More

Melanoma Research. 30(4):358-363, August 2020.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

Hintzsche, Jennifer D.; Gorden, Nicholas T.; Amato, Carol M.; More

Melanoma Research. 27(3):189-199, June 2017.

A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma

Mattei, Jane; Ballhausen, Alexej; Bassett, Roland; More

Melanoma Research. 30(6):574-579, December 2020.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

Ascierto, Paolo A.; Bastholt, Lars; Ferrucci, Pier F.; More

Melanoma Research. 28(4):333-340, August 2018.

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib

Vidarsdottir, Linda; Fernandes, Rita Valador; Zachariadis, Vasilios; More

Melanoma Research. 30(5):443-454, October 2020.

Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines

Cakir, Omer Onur; Pozzi, Edoardo; Castiglione, Fabio; More

Melanoma Research. 32(1):27-34, February 2022.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors

Awada, Gil; Schwarze, Julia Katharina; Tijtgat, Jens; More

Melanoma Research. 32(3):183-191, June 2022.

Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis

Yu, Irene S.; Wee, Kathleen; Williamson, Laura; More

Melanoma Research. : June 17, 2022

Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s)

Yano, Mitsutake; Nasu, Kaei; Yasuda, Masanori; More

Melanoma Research. 32(3):150-158, June 2022.

A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence

Kim, Kevin B.; Legha, Sewa S.; Gonzalez, Rene; More

Melanoma Research. 19(1):42-49, February 2009.

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Ahmad, Saif S.; Qian, Wendi; Ellis, Sarah; More

Melanoma Research. 25(5):432-442, October 2015.